Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

  • Quantitative Risk Model for Predicting Likelihood of Recurrence for Oral Cavity Cancer. Scott Doyle (Principal Investigator). NIH. $2,003,024. 4/1/2020-3/1/2024.
  • Collaborative Research: Control of Information Processing and Learning in Neuronal Networks through Light-mediated Programming of Genomic Networks. Yongho Bae (Co-Principal Investigator). National Science Foundation. $366,284. 2/1/2021-1/1/2024.
  • R01: Computational Imaging of Renal Structures for Diagnosing Diabetic Nephropathy. Pinaki Sarder (Principal Investigator). National Institutes of Health. $1,485,400. 9/1/2018-7/1/2023.
  • Biomarker Discovery and Validation in PSP. Olga Pletnikova (Contributor). NIH. $576,476. 8/1/2018-4/1/2023.
  • Networked Nanophotonic Devices for Stem Cell Regulation: From Optogenetics to Optogenomics. Yongho Bae (Co-Principal Investigator). National Science Foundation. $599,067. 8/1/2017-7/1/2022.
  • Mechanotransduction in Vascular Smooth Muscle: Survivin as a Mediator of Stiffness-Induced Responses. Yongho Bae (Principal Investigator). American Heart Association. $266,000. 7/1/2018-6/1/2022.
  • SBIR Phase II “A Blood-Based Test to Identify Patients with Intracranial Aneurysm”. John Kolega (Principal Investigator). Neurovascular Diagnostics, Inc. $24,891. 8/1/2019-7/1/2021.
  • Computerized histologic image predictor of cancer outcome. John Tomaszewski (Co-Investigator). NIH/Case. $232,187. 7/1/2016-6/1/2021.
  • University at Buffalo’s Center for Advanced Technology in Big Data and Health Sciences Total (UBCAT) “Molecular Markers for Dangerous Intracranial Aneurysms”. John Kolega (Principal Investigator). Neurovascular Diagnostics, Inc. $17,387. 7/1/2020-6/1/2021.
  • Integration of Physical and Virtual Cadavers in a Hybrid Gross Anatomy Curriculum. Scott Doyle (Co-Investigator). Center for Educational Innovation. $10,000. 5/1/2017-5/1/2021.
  • TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker The goal of this study to clarify mechanism of TDP-43 proteinopathy and perform target validation studies and develop biomarkers for ALS-FTD. Olga Pletnikova (Contributor). NIH. $250,000. 4/1/2016-3/1/2021.
  • Pathology Image Informatics Platform for visualization, analysis and management. John Tomaszewski (Co-Investigator). NIH/Case. $101,849. 7/1/2015-6/1/2020.
  • Alzheimer’s Disease before plaques and tangles: Abeta-Amyloid Oligomers and the Glymphatic Pathway The goal of this study is to generate novel information on very early development of Alzheimer’s disease to help identify new biomarkers for prevention and. Olga Pletnikova (Contributor). NIH. $150,000. 4/1/2017-3/1/2020.
  • Computational Analysis of Neutrophil Extracellular Traps in Lupus Nephritis Renal Biopsies. Pinaki Sarder (Principal Investigator). CKD Biomarkers Consortium Pilot and Feasibility Program. $75,000. 4/1/2019-3/1/2020.
  • Computational Imaging of Renal Structures for Diagnosing Diabetic Nephropathy. Pinaki Sarder (Principal Investigator). DiaComp Pilot & Feasibility Grant. $100,000. 11/1/2017-10/1/2019.